Drugs / Liquid Alpha1-Proteinase Inhibitor (Human)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04547140 | Jan → Dec 2021 | COVID-19 | Grifols Therapeutics LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liquid Alpha1-Proteinase Inhibitor (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04547140 ↗ |
| Route | Intravenous | “Intravenous infusion 120 mg/kg” NCT04547140 ↗ |